Efavirenz

Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. Among its listed roles, it functions as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes. Efavirenz is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in adults and in children. Efavirenz is always used in combination with other HIV medicines. It is grouped under the following drug class(es): Reverse Transcriptase Inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sustiva and Stocrin. Its PubChem CID is 64139.